Business
Newron Secures Up to EUR 38 Million to Advance Phase III Evenamide Program
MILAN, Italy & MORRISTOWN, N.J., February 16, 2026--Newron secures up to EUR 38 million to advance Phase III Evenamide program as potential first add-on therapy for treatment-resistant schizophrenia
About this update from Newron Pharmaceuticals S.p.a.
MILAN, Italy & MORRISTOWN, N.J., February 16, 2026--Newron secures up to EUR 38 million to advance Phase III Evenamide program as potential first add-on therapy for treatment-resistant schizophrenia
View stock analysis, news, and events for Newron Pharmaceuticals S.p.a.